Zambia SiVET MMR Tdap-IPV

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

May 16, 2017

Study Completion Date

May 16, 2017

Conditions
High Risk for HIV
Interventions
BIOLOGICAL

Tdap - IPV Vaccine

Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, combined with inactivated poliomyelitis vaccine (0.5 ml) will be administered intramuscularly.

BIOLOGICAL

MMR Vaccine

A live attenuated virus vaccine against measles, mumps and rubella (0.5 ml) will be administered intramuscularly.

Trial Locations (2)

Unknown

Zambia Emory HIV Research Project, Lusaka

Zambia Emory HIV Research Project, Ndola

All Listed Sponsors
collaborator

International AIDS Vaccine Initiative

NETWORK

collaborator

Zambia-Emory HIV Research Project

OTHER

lead

Emory University

OTHER

NCT02589678 - Zambia SiVET MMR Tdap-IPV | Biotech Hunter | Biotech Hunter